KRON Kronos Bio, Inc. Quarterly Revenue Growth

Symbol and logo of brand Kronos Bio Corporation (KRON)

Quarterly revenue changes demonstrate current income trends, where -25.90 determines the latest valuation metric for Kronos Bio, Inc. (KRON). This results from management's strategy to optimize expenses and narrow the R&D portfolio. The business relies on the development of targeted drugs against tumor transcription factors under FDA supervision. The growth potential is immense: minimal production costs upon drug approval guarantee high margins.

Kronos Bio Corporation (KRON) - Quarterly Revenue Growth Rate from 07/04/2022 to 06/28/2025

Kronos Bio (KRON) - metric breakdowns and financial figures

- current quotes and average value forecast:
General company analysis:Kronos Bio Inc (KRON)
Flagship merchandise of kronosbio.com

This indicator calculates the percentage deviation of current revenue from the value of the same quarter last year, measuring business scaling rates through top-line report dynamics. The current value of -25.90 allows for an assessment of the commercial efficiency of the Kronos Bio, Inc. (KRON) innovative oncology platform, where the quarterly revenue change metric serves as a marker of market demand for the therapeutic solutions under development.